WAVE LIFE SCIENCES LTD. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
WAVE LIFE SCIENCES LTD. (WVE) had Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of 3.18 million shares as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber · last filed 2026-07-30
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 3.18M shares.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 3.24M shares.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 1.79M shares.
- 2025-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 1.83M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number |
|---|---|
| 2026-06-30 | 3.18M shares 10-Q · filed 2026-07-30 |
| 2026-03-31 | 3.24M shares 10-Q · filed 2026-04-28 |
| 2025-09-30 | 1.79M shares 10-Q · filed 2025-11-10 |
| 2025-06-30 | 1.83M shares 10-Q · filed 2026-07-30 |
| 2025-03-31 | 1.79M shares 10-Q · filed 2026-04-28 |
| 2024-09-30 | 827.24K shares 10-Q · filed 2025-11-10 |
| 2024-06-30 | 660.75K shares 10-Q · filed 2025-07-30 |
| 2024-03-31 | 635.32K shares 10-Q · filed 2025-05-08 |
| 2023-09-30 | 633.28K shares 10-Q · filed 2024-11-12 |
| 2023-06-30 | 626.47K shares 10-Q · filed 2024-08-08 |
| 2023-03-31 | 614.45K shares 10-Q · filed 2024-05-10 |
| 2022-09-30 | 999.77K shares 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |